CPIC指南药物药物基因组学检测的成本效果系统综述
该系统综述纳入108项研究评估39种药物的药物基因组学(PGx)检测成本效果,其中77项(71%)显示PGx检测具有成本效果(48项)或节省成本(29项);氯吡格雷相关研究最多(23篇,22篇支持),HLA检测相关26篇中15篇支持。多数研究支持PGx检测,但抢先检测和多基因检测数据有限。
要点
- 多数CPIC指南药物的PGx检测具成本效果或节省成本。
- 氯吡格雷PGx检测成本效果证据最充分(23篇中22篇支持)。
- 抢先检测和多基因检测的成本效果数据有限。
核心结论
- 多数评估CPIC指南药物PGx检测成本效果的研究支持PGx检测具有成本效果或节省成本。
研究设计与样本
- 系统综述检索多个生物医学文献数据库至2021年6月,纳入比较PGx指导与非指导治疗的全篇文章,共108项研究评估39种药物。
- 使用健康经济研究质量(QHES)量表(0-100分)评估研究稳健性,中位QHES评分为91分(范围48-100),反映高质量研究。
主要发现
- 108项研究中77项(71%)显示PGx检测具成本效果(48项)或节省成本(29项);21项(20%)不具成本效果;10项(9%)不确定。
- 氯吡格雷相关文章最多(23篇),其中22篇显示成本效果或节省成本;华法林相关16篇中7篇显示成本效果或节省成本。
- 26项评估HLA检测的研究(阿巴卡韦8项、别嘌醇10项、卡马西平/苯妥英8项)中15项显示成本效果或节省成本。
- 11篇抗抑郁药相关文章中9篇显示成本效果或节省成本。
临床怎么用
- 临床可优先参考证据充分的药物(如氯吡格雷)开展PGx检测以优化成本效果。
局限性
- 抢先检测和多基因检测跨疾病状态的成本效果数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The objective of this study was to evaluate the evidence on cost-effectiveness of pharmacogenetic (PGx)-guided treatment for drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines. A systematic review was conducted using multiple biomedical literature databases from inception to June 2021. Full articles comparing PGx-guided with nonguided treatment were included for data extraction. Quality of Health Economic Studies (QHES) was used to assess robustness of each study (0-100). Data are reported using descriptive statistics. Of 108 studies evaluating 39 drugs, 77 (71%) showed PGx testing was cost-effective (CE) (N = 48) or cost-saving (CS) (N = 29); 21 (20%) were not CE; 10 (9%) were uncertain. Clopidogrel had the most articles (N = 23), of which 22 demonstrated CE or CS, followed by warfarin (N = 16), of which 7 demonstrated CE or CS. Of 26 studies evaluating human leukocyte antigen (HLA) testing for abacavir (N = 8), allopurinol (N = 10), or carbamazepine/phenytoin (N = 8), 15 demonstrated CE or CS. Nine of 11 antidepressant articles demonstrated CE or CS. The median QHES score reflected high-quality studies (91; range 48-100). Most studies evaluating cost-effectiveness favored PGx testing. Limited data exist on cost-effectiveness of preemptive and multigene testing across disease states.
引用
- Morris SA, Alsaidi AT, Verbyla A, et al. Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic Review. Clin Pharmacol Ther. 2022. PMID: 36149409. doi:10.1002/cpt.2754
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。